ERBB2 and breast cancer: Additionally, lower pCR rates were observed in HER2+ BC patients with PIK3CA alterations than without PIK3CA alterations, even though the association between PI3K-AKT pathway biomarkers and docetaxel benefit was not identified (44–46).